Table 1 Clinical characteristics and treatment of 216 patients with multiple myeloma
Characteristics | IgD subtype | Non-IgD subtypes | P value |
|---|---|---|---|
Cases, n | 13 | 203 | Â |
Age [years; median (range)] | 52 (44–66) | 60 (24–82) | 0.028 |
Sex [cases (%)] | 0.782 | ||
 Male | 8 (61.5) | 117 (57.3) |  |
 Female | 5 (38.5) | 86 (42.7) |  |
Hemoglobin [g/L; mean (range)] | 73 (44–108) | 90 (40–107) | 0.011 |
Platelets < 100 × 109/L [cases (%)] | 4 (30.8) | 32 (15.8) | 0.306 |
Light chain type [cases (%)] | 0.006 | ||
 κ | 1 (7.7) | 104 (51.2) |  |
 λ | 12 (92.3) | 99 (48.8) |  |
Creatinine > 2 mg/dL [cases (%)] | 9 (69.2) | 47 (23.2) | < 0.001 |
β2M [mg/L; mean (range)] | 10 (2.57–16.50) | 5.16 (1.45–19.40) | 0.001 |
Bone lesion [cases (%)] | 10 (76.9) | 170 (83.7) | 0.459 |
Hypercalcemia [cases (%)] | 3(23.1) | 14 (6.9) | 0.117 |
Urine protein (g/L) | 3.20 (0.15–19.69) | 1.30 (0.10–26.10) | 0.196 |
LDH > 250 U/L [cases (%)] | 7 (53.8) | 37 (18.2) | 0.002 |
ISS stage [cases (%)] | 0.002 | ||
 I | 0 | 41 (20.2) |  |
 II | 0 | 58 (28.6) |  |
 III | 13 (100.0) | 104 (50.2) |  |
Induction therapy [cases (%)] | 0.080 | ||
 IMiD-based regimens | 4 (30.8) | 121(59.6) |  |
 Bortezomib-based regimens | 9 (69.2) | 82 (40.4) |  |
Final response [cases (%)] | 0.847 | ||
 sCR, CR | 4 (30.8) | 68 (33.5) |  |
 VGPR | 3 (23.1) | 80 (39.4) |  |
 PR | 4 (30.8) | 43 (20.9) |  |
 SD plus PD | 2 (15.4) | 12 (5.8) |  |
AL amyloidosis [cases (%)] | 4 (30.8) | 8 (3.9) | 0.001 |
Extramedullary infiltration [cases (%)] | 2 (15.4) | 57 (28.1) | 0.500 |